Medicus Pharma Ltd. Common Stock(MDCX)Earnings, Financials & Key Ratios

MDCX•NASDAQ

$0.46

Price updated Jul 6, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryOncology Therapeutics Developers

AboutMedicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets, with an emphasis on non-invasive treatments for skin cancer.Show more

Revenue$0
EBITDA-$18M-64.5%
Net Income-$25M-127.4%
EPS (Diluted)-1.96-69.0%
ROE-1599.39%-204.4%

MDCX Price & Volume

Medicus Pharma Ltd. Common Stock (MDCX) stock price & volume — 10-year historical chart

Loading chart...

Clinical Development Costs Outpace Capital Reserves

Investment Thesis • Updated 2026Q1

VerdictNegative

Growth:Mixed

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Clinical-stage liquidity shortfall

Key Thesis Takeaways

Medicus Pharma remains a high-risk, clinical-stage entity characterized by persistent net losses and a lack of recurring revenue, which necessitates frequent reliance on external financing.
While the company advances its SkinJect platform, the erosion of equity to a deficit of $49.3K in 2025Q4 and the consistent negative free cash flow suggest significant long-term solvency concerns.
Investors should monitor the company's ability to secure non-dilutive capital, as the current debt-to-equity ratio of 146.80 in 2025Q4 highlights a precarious financial structure.

Verdict Logic

the company's fundamental outlook is constrained by a consistent history of negative free cash flow, including a $6.5 million outflow in 2026Q1, and a precarious balance sheet with an equity deficit of $49.3K reported in 2025Q4.

MDCX Growth Metrics

Medicus Pharma Ltd. Common Stock (MDCX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-

3 Years-

TTM-

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM-155.31%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM-48.65%

Return on Capital

10 Years-662.46%

5 Years-662.46%

3 Years-662.46%

Last Year-1059.55%

Latest MDCX News

Recent stock market news and headlines for Medicus Pharma Ltd. Common Stock (MDCX)

GlobeNewsWire·Jun 22, 2026

Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026

Company's presentation will provide updates on SkinJect® Phase 2b Pivotal Study in patients with Gorlin Syndrome and Teverelix® Groundbreaking PRECISION-E2 Phase 2a Endometriosis Study leveraging the UAE Genome Program Company's presentation will provide updates on SkinJect® Phase 2b Pivotal Study in patients with Gorlin Syndrome and Teverelix® Groundbreaking PRECISION-E2 Phase 2a Endometriosis Study leveraging the UAE Genome Program

Proactive Investors·Jun 20, 2026

Medicus Pharma advances Teverelix in prostate cancer - ICYMI

Medicus Pharma (NASDAQ:MDCX) earlier this week announced the submission of a key European regulatory package designed to support the launch of a Phase 2b clinical study of Teverelix in advanced prostate cancer patients with elevated cardiovascular risk. Speaking with Proactive, chief medical officer Dr Faisal Mehmud said the filing represents an important regulatory milestone for the programme and marks a significant step toward advancing the company's development strategy in an underserved patient population.

Proactive Investors - Finance·Jun 20, 2026

Medicus Pharma advances Teverelix in prostate cancer - ICYMI

Medicus Pharma (NASDAQ:MDCX) earlier this week announced the submission of a key European regulatory package designed to support the launch of a Phase 2b...

Peers Comparison

Key metrics vs top competitors for Medicus Pharma Ltd. Common Stock (MDCX)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
MDCXMedicus Pharma Ltd. Common StockCurrent	$0.46	$10.14M	-0.23	—	—	-1599.39%	—
SIGASIGA Technologies, Inc.	$3.75	$268.97M	11.36	-31.8%	21.61%	10.62%	—
NUVBNuvation Bio Inc.	$5.60	$1.94B	-9.33	698.96%	-102.06%	-44.1%	—
IMVTImmunovant, Inc.	$38.60	$7.92B	-13.94	—	—	-68.16%	—
TPVGTriplePoint Venture Growth BDC Corp.	$4.79	$194.47M	3.93	36.55%	-19.55%	-3.39%	—
DERMJourney Medical Corporation	$7.22	$198.71M	-15.36	10.2%	-14.82%	-35.57%	—